Here’s What to Know About Pfizer’s New COVID-19 Vaccine, Proved to Be 90% Effective After Phase III Study

By  //  November 10, 2020

Share on Facebook Share on Twitter Share on LinkedIn Share on Delicious Digg This Stumble This

Cost: $39. vaccine requires two doses, three weeks apart

ABOVE VIDEO: Dr. Siegel breaks down Pfizer coronavirus vaccine, distribution.

(FOX BUSINESS) – Pfizer and its German partner BioNTech disclosed a game-changer in the fight against COVID-19.

The duo’s vaccine, known as BNT162b2, proved to be 90% effective after being tested on nearly 44,000 participants in its Phase III study. This is a significant milestone in the fight against a virus that has infected more than 50 million people around the globe, resulting in over 1.2 million deaths.

FOX Business takes a look at the key data points investors and consumers should know, as well as reactions from business and political leaders.

“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Pfizer CEO and Chairman Dr. Albert Bourla, in a statement.

“We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen. With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis.”